This work was funded by the U.S. Army Medical Research and Medical Command (grant: F_025_2010_USAISR) awarded to T.J.W., and National Institutes of Health grant awarded to J.M. All animal protocols were approved by the U.S. Army Institute of Surgical Research Animal Care and Use Committee. This study adhered to National Institutes of Health guidelines for the care and use of laboratory animals (DHHS Publication, NIH, 86 to 23). All components of this study including the decision where to publish were at the sole discretion of the authors. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of Defense (AR 360-5) or the United States Government. Some of the authors are employees of the U.S. government, and this work was prepared as part of their official duties.
Effect of recombinant human MG53 protein on tourniquet-induced ischemia-reperfusion injury in rat muscle
Article first published online: 17 MAY 2014
Published 2014 by Wiley Periodicals, Inc. This article is a US Government work and, as such, is in the public domain in the United States of America.
Muscle & Nerve
Volume 49, Issue 6, pages 919–921, June 2014
How to Cite
Corona, B. T., Garg, K., Roe, J. L., Zhu, H., Park, K. H., Ma, J. and Walters, T. J. (2014), Effect of recombinant human MG53 protein on tourniquet-induced ischemia-reperfusion injury in rat muscle. Muscle Nerve, 49: 919–921. doi: 10.1002/mus.24160
- Issue published online: 17 MAY 2014
- Article first published online: 17 MAY 2014
- Accepted manuscript online: 3 JAN 2014 01:10AM EST
- Manuscript Accepted: 30 DEC 2013
- muscle injury;
Introduction: Skeletal muscle ischemia–reperfusion injury (I-R) is a complex injury process that includes damage to the sarcolemmal membrane, contributing to necrosis and apoptosis. MG53, a muscle-specific TRIM family protein, has been shown to be essential for regulating membrane repair and has been shown to be protective against cardiac I-R and various forms of skeletal muscle injury. The purpose of this study was to determine if recombinant human MG53 (rhMG53) administration offered protection against I-R. Methods: rhMG53 was administered to rats immediately before tourniquet-induced ischemia and again immediately before reperfusion. Two days later muscle damage was assessed histologically. Results: rhMG53 offered no protective effect, as evidenced primarily by similar Evans blue dye inclusion in the muscles of rats administered rhMG53 or saline. Conclusions: Administration of rhMG53 does not offer protection against I-R in rat skeletal muscle. Additional studies are required to determine if the lack of a response is species-specific. Muscle Nerve 49: 919–921, 2014